Phospho-SP1 (T453) Antibody

What is Phospho-SP1 (T453) Antibody and what cellular processes does it help investigate?

Phospho-SP1 (T453) antibody is a specialized immunological reagent that specifically recognizes the transcription factor SP1 when phosphorylated at threonine 453. This antibody allows researchers to study the phosphorylation state of SP1, which is crucial for understanding its functional regulation. SP1 (Specificity Protein 1) is a ubiquitous transcription factor that regulates numerous cellular processes, and its phosphorylation at T453 has been implicated in multiple biological contexts, including cancer progression, gene expression regulation, and viral infection response mechanisms .

The methodological value of this antibody stems from its ability to discriminate between phosphorylated and non-phosphorylated forms of SP1, enabling researchers to investigate dynamic signaling events that modify SP1 activity. Recent research has demonstrated that phosphorylation at T453 significantly influences SP1's nuclear localization and transcriptional activity, particularly in contexts such as breast cancer invasion, mechanotransduction, and regulation of the SARS-CoV-2 receptor ACE2 .

What applications is Phospho-SP1 (T453) Antibody validated for?

Phospho-SP1 (T453) antibody has been validated for multiple experimental applications, each requiring specific optimization protocols:

• Western Blotting (WB): Recommended dilutions typically range from 1:500 to 1:1000. The expected molecular weight of SP1 is approximately 80 kDa, which has been confirmed in various cell lysates including H1688 cells .

• Immunohistochemistry (IHC): Optimal dilutions range from 1:50 to 1:200. For formalin-fixed paraffin-embedded tissues, heat-mediated antigen retrieval with sodium citrate buffer (pH 6.0) is often necessary before antibody incubation .

• Immunofluorescence (IF)/Immunocytochemistry (IC): Recommended dilutions range from 1:100 to 1:500. Cells typically require permeabilization with 0.1% Triton X-100 in TBS for 5-10 minutes and blocking with 3% BSA-PBS for 30 minutes at room temperature before overnight antibody incubation at 4°C .

• Chromatin Immunoprecipitation (ChIP): This application requires concentration-dependent optimization based on the specific experimental conditions .

Each application requires specific optimization depending on the experimental system, including cell type, tissue origin, and expression levels of phosphorylated SP1.

What controls should be included when working with Phospho-SP1 (T453) Antibody?

Proper experimental controls are essential for validating results obtained with phospho-SP1 (T453) antibody:

• Phosphopeptide Competition: Preincubation of the diluted antibody with molar excess of the immunizing phosphopeptide should abolish immunoreactivity, while the corresponding dephosphopeptide should not affect antibody binding. This confirms phospho-specificity of the antibody .

• Enzymatic Dephosphorylation: Treatment of samples with alkaline phosphatase prior to antibody incubation should eliminate phospho-SP1 (T453) signal, confirming the phospho-specificity of the detected epitope .

• Positive Controls: Cell lines or tissues with known SP1 phosphorylation status, such as H1688 cells for Western blotting or breast cancer tissues for immunohistochemistry, provide useful positive controls .

• Negative Controls: Primary antibody omission controls and isotype-matched irrelevant antibody controls should be included to assess non-specific binding.

• Modulation Controls: Treatments known to modulate SP1 phosphorylation, such as ERK1/2 inhibitor SCH77298 or PI3K inhibitor LY294002, which have been shown to decrease phospho-SP1 nuclear localization, can serve as functional controls .

How should Phospho-SP1 (T453) Antibody be stored and handled to maintain activity?

Proper storage and handling of phospho-SP1 (T453) antibody is crucial for maintaining its activity and specificity:

• Long-term Storage: Store at -20°C for up to one year. The antibody is typically supplied in a buffer containing stabilizers such as 0.42% potassium phosphate, 0.87% sodium chloride, pH 7.3, 30% glycerol, and 0.01% sodium azide .

• Short-term Storage: For frequent use over periods of up to one month, storage at 4°C is recommended .

• Avoid Freeze-Thaw Cycles: Repeated freeze-thaw cycles can degrade antibody quality. It is advisable to prepare small aliquots before freezing to minimize the number of freeze-thaw cycles .

• Working Dilutions: Prepare working dilutions fresh before use, and store diluted antibody at 4°C for no longer than 24 hours.

• Sample Stability: Phosphoepitopes can be labile, so samples should be processed quickly and maintained with phosphatase inhibitors to preserve phosphorylation status .

How does phosphorylation at T453 affect SP1's nuclear localization and transcriptional activity?

Phosphorylation of SP1 at T453 significantly influences its cellular localization and transcriptional function:

• Nuclear Localization: Research has demonstrated that phosphorylated SP1 (T453) preferentially localizes to the nucleus, where it can access its DNA targets. In breast cancer cells exposed to tumor-mimicking extracellular matrix conditions, increased nuclear-to-cytoplasmic ratio of phospho-SP1 (T453) correlates with invasive phenotypes . The nuclear localization can be quantified using the nuclear-to-cytoplasmic intensity ratio in immunofluorescence studies .

• Transcriptional Activity: Phosphorylation at T453 enhances SP1's transcriptional activity. Studies have shown that SP1 phosphorylation increases its capacity to activate target genes involved in various cellular processes, including cancer progression and viral receptor expression .

• Protein-Protein Interactions: Phosphorylated SP1 exhibits altered interactions with other transcription factors and cofactors. For instance, SP1 has been shown to interact with proteins like E1AF and HNF4α, with these interactions potentially being modulated by its phosphorylation status .

Experimental approach: To investigate the relationship between SP1 phosphorylation and its nuclear localization, researchers can perform immunofluorescence using phospho-SP1 (T453) antibody together with nuclear staining, followed by quantification of the nuclear-to-cytoplasmic intensity ratio. The impact on transcriptional activity can be assessed using reporter assays with SP1-responsive promoter constructs, comparing conditions that enhance or inhibit SP1 phosphorylation .

What kinases regulate SP1 phosphorylation at T453 and how can they be experimentally modulated?

Multiple kinases have been identified as regulators of SP1 phosphorylation at T453, providing opportunities for experimental manipulation:

• ERK1/2 (Extracellular Signal-Regulated Kinases): Research has demonstrated that ERK1/2 can phosphorylate SP1 at T453. Inhibition of ERK1/2 using specific inhibitors such as SCH77298 leads to decreased phospho-SP1 nuclear localization and altered cellular phenotypes in models of breast cancer invasion .

• PI3K (Phosphoinositide 3-Kinase): PI3K signaling also contributes to SP1 phosphorylation at T453. Treatment with the PI3K inhibitor LY294002 results in reduced phospho-SP1 nuclear localization, particularly in cells exposed to high matrix stiffness .

• Other Potential Kinases: Additional kinases involved in SP1 phosphorylation may include cyclin-dependent kinases (CDKs) and JNK, though their specific roles in T453 phosphorylation require further investigation.

Experimental modulation approaches:

• Pharmacological inhibition using specific inhibitors (SCH77298 for ERK1/2, LY294002 for PI3K)

• Genetic approaches (siRNA knockdown, CRISPR/Cas9 gene editing)

• Upstream pathway activation or inhibition

• Site-directed mutagenesis of the T453 site (T453A to prevent phosphorylation or T453D/E to mimic constitutive phosphorylation)

A comprehensive approach would involve combining these methods with phospho-SP1 (T453) detection to establish causative relationships between specific kinases and SP1 phosphorylation .

How can Phospho-SP1 (T453) Antibody be used to investigate mechanotransduction in cancer?

Recent research has revealed an important role for SP1 phosphorylation in mechanotransduction, particularly in breast cancer invasion. Phospho-SP1 (T453) antibody can be utilized to investigate this process through several methodological approaches:

• Matrix Stiffness Studies: Recent research has demonstrated that SP1 phosphorylation at T453 increases in response to tumor-mimicking extracellular matrix properties, including increased stiffness and altered stress relaxation characteristics. In MDA-MB-231 breast cancer cells, increased nuclear localization of phospho-SP1 correlates with invasive morphologies in various matrix conditions .

• Experimental Approach:

  • Culture cells in hydrogels with tunable mechanical properties

  • Perform immunofluorescence staining with phospho-SP1 (T453) antibody

  • Quantify nuclear-to-cytoplasmic ratio of phospho-SP1

  • Correlate with invasive morphology parameters (roundness, cluster area)

  • Manipulate mechanosensing pathways using inhibitors of ERK1/2 or PI3K

  • Assess impact on SP1 phosphorylation and cellular phenotype

• Mechanical Force Application: Direct mechanical force application has also been shown to modulate SP1 phosphorylation. Researchers can combine techniques such as magnetic twisting cytometry or substrate stretching with phospho-SP1 (T453) immunofluorescence to investigate acute mechanotransduction .

This experimental framework allows researchers to establish causal relationships between mechanical stimuli, SP1 phosphorylation, and cellular behaviors relevant to cancer progression .

What is the role of Phospho-SP1 (T453) in regulating SARS-CoV-2 receptor ACE2 expression?

Recent research has identified SP1 as a novel regulator of ACE2 expression, which is significant in the context of SARS-CoV-2 infection. Phospho-SP1 (T453) antibody can be used to investigate this regulatory mechanism:

• Transcriptional Regulation: SP1 has been shown to regulate the expression of ACE2, the primary receptor for SARS-CoV-2. Phosphorylation of SP1 may influence its capacity to regulate ACE2 gene expression .

• Antagonistic Relationship with HNF4α: SP1 and HNF4α exert opposing effects on ACE2 expression. Interestingly, treatment with an HNF4α antagonist (BI6015) increases SP1 phosphorylation at T453, while the SP1 inhibitor mithramycin A (MithA) suppresses SP1 phosphorylation .

• Protein-Protein Interactions: Co-immunoprecipitation assays have confirmed interactions between SP1 and HNF4α, suggesting that these proteins may antagonize each other through direct protein-protein interactions .

Experimental approach for investigating this pathway:

• Modulate SP1 activity using mithramycin A or siRNA knockdown

• Assess ACE2 expression levels using qRT-PCR and Western blotting

• Monitor SP1 phosphorylation status using phospho-SP1 (T453) antibody

• Investigate SP1-HNF4α interactions using co-immunoprecipitation

• Correlate changes in SP1 phosphorylation with ACE2 expression and cellular susceptibility to SARS-CoV-2 infection

These methods can help elucidate the role of phosphorylated SP1 in regulating viral receptor expression and potentially identify novel therapeutic targets for viral infections .

What technical challenges might arise when using Phospho-SP1 (T453) Antibody and how can they be overcome?

Working with phospho-specific antibodies presents several technical challenges that researchers should consider:

• Phosphoepitope Lability: Phosphorylated proteins are susceptible to rapid dephosphorylation by endogenous phosphatases. To preserve phosphorylation status:

  • Process samples rapidly and maintain at cold temperatures

  • Include phosphatase inhibitors in all buffers (e.g., sodium fluoride, sodium orthovanadate, β-glycerophosphate)

  • Use freshly prepared fixatives for IHC/IF applications

• Specificity Concerns: Ensuring phospho-specificity is crucial for reliable results:

  • Perform phosphopeptide competition assays to confirm specificity

  • Include alkaline phosphatase-treated samples as negative controls

  • Validate antibody specificity using cells treated with kinase inhibitors that reduce SP1 phosphorylation

• Signal-to-Noise Ratio: Optimizing signal-to-noise ratio is important for detecting specific signals:

  • Titrate antibody concentrations carefully

  • Optimize blocking conditions (3% BSA-PBS has been effective for phospho-SP1)

  • For IHC, heat-mediated antigen retrieval with sodium citrate buffer (pH 6.0) improves detection

• Quantification Challenges: Accurate quantification of phosphorylation levels requires:

  • Include appropriate controls for normalization

  • Use nuclear-to-cytoplasmic ratio for IF/IC rather than absolute intensities

  • Consider dual staining with total SP1 antibody to normalize phospho-signal to total protein

• Context Dependency: SP1 phosphorylation may vary significantly across cell types and conditions:

  • Include relevant biological controls

  • Be aware that basal phosphorylation levels may differ between cell lines (e.g., non-malignant MCF-10A cells show high basal phospho-SP1 levels compared to MDA-MB-231)

Addressing these challenges through careful experimental design and appropriate controls will help ensure reliable and reproducible results when working with phospho-SP1 (T453) antibody.

How should I design experiments to study SP1 phosphorylation dynamics in response to stimuli?

Investigating SP1 phosphorylation dynamics requires careful experimental design:

• Time Course Analysis: Design experiments with multiple time points to capture the temporal dynamics of SP1 phosphorylation in response to stimuli of interest:

  • Short time points (minutes to hours) to capture immediate phosphorylation events

  • Longer time points (hours to days) to investigate sustained effects

  • Western blotting with phospho-SP1 (T453) antibody at each time point, normalized to total SP1

• Dose-Response Relationships: Establish dose-response curves for stimuli that modulate SP1 phosphorylation:

  • Vary concentrations of stimuli (growth factors, inhibitors, mechanical stimuli)

  • Quantify phospho-SP1 levels using immunoblotting or immunofluorescence

  • Plot dose-response curves to identify threshold effects

• Subcellular Fractionation: Separate nuclear and cytoplasmic fractions to precisely quantify SP1 phosphorylation in different cellular compartments:

  • Use validated fractionation protocols with proper markers for each compartment

  • Apply phospho-SP1 (T453) antibody to detect phosphorylated SP1 in each fraction

  • Calculate the ratio of nuclear to cytoplasmic phospho-SP1 as a measure of nuclear translocation

• Single-Cell Analysis: For heterogeneous populations, use immunofluorescence with phospho-SP1 (T453) antibody to analyze cell-to-cell variability:

  • Quantify nuclear-to-cytoplasmic ratio at the single-cell level

  • Create frequency distributions of phosphorylation levels across the population

  • Identify potential subpopulations with distinct phosphorylation patterns

• Multiplexed Analysis: Combine phospho-SP1 detection with markers of cellular processes of interest:

  • Co-stain with markers of cell cycle, differentiation, or stress

  • Use multi-parameter flow cytometry or imaging to correlate SP1 phosphorylation with cellular states

These approaches allow for comprehensive characterization of SP1 phosphorylation dynamics in response to various experimental manipulations .

How can I integrate Phospho-SP1 (T453) analysis with other protein-protein interaction studies?

Investigating interactions between phosphorylated SP1 and other proteins requires integrated experimental approaches:

• Co-immunoprecipitation (Co-IP) with Phospho-Specific Detection:

  • Immunoprecipitate with antibodies against potential SP1 interacting partners

  • Probe immunoprecipitates with phospho-SP1 (T453) antibody to detect interactions specific to the phosphorylated form

  • Include ethidium bromide (EtBr) treatment to rule out DNA-mediated interactions

• Reverse Co-IP Approach:

  • Immunoprecipitate with phospho-SP1 (T453) antibody

  • Probe for co-precipitating proteins of interest

  • Compare with immunoprecipitation using total SP1 antibody to identify interactions specific to the phosphorylated form

• Domain Mapping:

  • Generate SP1 mutants with specific domain deletions or modifications

  • Combine with site-directed mutagenesis of T453 (T453A to prevent phosphorylation)

  • Assess impact on protein-protein interactions using co-IP approaches

  • Example: Studies have shown that the Gln-rich domain B of SP1 is required for interaction with E1AF, and this interaction may be influenced by phosphorylation status

• Functional Validation through Transcriptional Assays:

  • Use reporter constructs containing SP1-binding sites

  • Co-express SP1 with potential interacting partners

  • Manipulate phosphorylation status through kinase inhibitors or phospho-mimetic mutations

  • Assess impact on transcriptional activity

  • Example: E1AF has been shown to enhance transactivation by SP1 in a manner that may depend on phosphorylation status

• Proximity Ligation Assay (PLA):

  • Combine phospho-SP1 (T453) antibody with antibodies against potential interacting proteins

  • Visualize and quantify protein-protein interactions in situ

  • Correlate with cellular conditions that modulate SP1 phosphorylation

These integrated approaches can help establish relationships between SP1 phosphorylation status and its protein interaction network, providing insights into how phosphorylation regulates SP1 function in various cellular contexts .